Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studiesMatteo Lambertini, Lucia Del Mastro, Marco Benasso et al.|European Journal of Cancer|2016Cited by 44
LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineNicoletta Colombo, Andrés Poveda, Angiolo Gadducci et al.|Annals of Oncology|2020Cited by 23
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)Stefania Gori, Lucia Del Mastro, Fabio Puglisi et al.|European Journal of Cancer|2018Cited by 13
Effect modifiers in a randomized phase III trial of low-dose tamoxifen in breast preinvasive disease.Andrea De Censi, Bernardo Bonanni, Matteo Puntoni et al.|Journal of Clinical Oncology|2019Cited by 3
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Alessandra Gennari, Nadia Harbeck, Étienne Brain et al.|Journal of Clinical Oncology|2023Cited by 2